Arrivent Biopharma, Inc. · NASDAQ:AVBP
Arrivent Biopharma — Investor Presentation (August 2026)
21 slides from Arrivent Biopharma's investor presentation, August 2026
Slide 1: A Late-Stage Company With a Global Oncology Portfolio
A Late-Stage Company With a Global Oncology Portfolio August 2026 Corporate Presentation
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements include, but are not limited to, implied and express statements about our strategy, business
Slide 3: ArriVent BioPharma: A Late-Stage Company With Multiple Assets in Clinical Development
Accelerating a differentiated oncology pipeline built through strategic partnerships with innovative companies globally ArriVent BioPharma: A Late-Stage Company With Multiple Lead program firmonertinib with Breakthrough Therapy and Orphan designation in 1L EGFR exon 20 insertion mutant NSCLC Assets
Slide 4: Firmonertinib: Broad-spectrum EGFR Inhibitor Structurally Differentiated to Address Underserved Uncommon EGFRm NSCLC
Firmonertinib: Broad-spectrum EGFR Inhibitor Structurally Differentiated to Address Underserved Uncommon EGFRm NSCLC Active against both classical and uncommon EGFR mutations Potentially Best-In-Class Highly brain penetrant First Line Option Orally bioavailable with pharmacokinetic properties to sup
Slide 5: Robust Pipeline to Maximize Impact Across Indications & Geographies
Robust Pipeline to Maximize Impact Across Indications & Geographies Program Target Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 ArriVent Rights Partner 1L NSCLC EGFR exon 20 Monotherapy Global-Ex China Insertion Mutations BTD Firmonertinib 1L NSCLC EGFR PACC EGFR TKI Monotherapy Global-E
Slide 6: EGFR Mutant NSCLC Is One of the Most Prevalent Types of Cancer
EGFR Mutant NSCLC Is One of the Most Prevalent Types of Cancer EGFR NSCLC Mutations NSCLC Uncommon EGFR Mutations Global Incidence (Excluding Greater China) > 100K Uncommon EGFR Mutations 30.8% PACC (incl. compound) 12.5% 31K Exon 20 insertions 9.1% 42K >100K Pt’s Other uncommon (incl. L861Q) 9.2% C
Slide 7: FAVOUR Study Design: EGFR exon 20 Insertion Mutant NSCLC
FAVOUR Study Design: EGFR exon 20 Insertion Mutant NSCLC (NCT: 04858958) Key Inclusion Criteria Treatment naïve • Locally advanced or Firmonertinib 240 mg/day Treatment until metastatic NSCLC n=30 • Disease • Presence of EGFR Follow up progression exon 20 insertion Previously treated every 6 weeks m
Slide 8: FAVOUR: Robust Responses to Firmonertinib Monotherapy in EGFR exon 20 Insertion NSCLC
FAVOUR: Robust Responses to Firmonertinib Monotherapy in EGFR exon 20 Insertion NSCLC Across All Mutation Subtypes 40 Treatment Naïve 240mg Previously Treated 240mg Previously Treated 160mg N=28 N=26 ○ N=26 Best Percent Change of Tumor 20 Size from Baseline (%) ○□○∆○○○∆○○○∆ x ∆○∆○○○○∆○□○∆∆ x ○ ∆ ○ ○
Slide 9: FAVOUR: Responses Were Rapid and Durable
FAVOUR: Responses Were Rapid and Durable • Most responses occur at the first tumor assessment (6 weeks) • The longest DoR is beyond 26 months with treatment ongoing Data Cut: 15 Jun 2023 8
Slide 10: FURVENT: A Global Phase 3 Trial in 1L NSCLC EGFR exon 20 Insertion Mutations
FURVENT: A Global Phase 3 Trial in 1L NSCLC EGFR exon 20 Insertion Mutations (NCT: 05607550) Firmonertinib Primary Key Inclusion Criteria: 160 mg QD endpoint: Non-squamous locally advanced or metastatic NSCLC with EGFR exon 20 PFS by BICR per insertion mutation RECIST v1.1 No prior systemic anticanc
Slide 11: FURTHER: A Global Phase 1b Study Evaluating Firmonertinib Monotherapy in NSCLC EGFR PACC Mutations
FURTHER: A Global Phase 1b Study Evaluating Firmonertinib Monotherapy in NSCLC EGFR PACC Mutations (NCT: 05364073) Stage 2 Cohort 4 Dose Expansion Key Eligibility Criteria: Endpoints • Locally advanced or metastatic NSCLC with EGFR PACC mutations Primary endpoints: Firmonertinib • No prior EGFR TKI
Slide 12: FURTHER: Firmonertinib Showed Strong Confirmed Overall Responses for 1L NSCLC EGFR PACC Mutations
FURTHER: Firmonertinib Showed Strong Confirmed Overall Responses (BICR) for 1L NSCLC EGFR PACC Mutations 160 mg QD 240 mg QD n=23 n=22 Best ORR, % (95% CI)a 52.2% (30.6–73.2) 81.8% (59.7–94.8) Confirmed ORR, % (95% CI) 43.5% (23.2–65.5) 68.2% (45.1–86.1) Best overall response, n (%) Complete respons
Slide 13: FURTHER: Median PFS is Clinically Meaningful in 1L NSCLC EGFR PACC Mutations
FURTHER: Median PFS is Clinically Meaningful in 1L NSCLC EGFR PACC Mutations PFS HR favors 240mg as the optimal dose for Phase 3 160 mg QD 11.1 months (6.6, NR) 240 mg QD PFS Probability (%) 16.0 months mPFS (240 mg) 16.0 months (11.0, NA) (12.5, NA) HR (95% CI) 0.834 (0.373 – 1.863), p = 0.6524 Fin
Slide 14: FURTHER: CNS Activity Including Complete CNS Responses in PACC Cohort
FURTHER: CNS Activity Including Complete CNS Responses in PACC Cohort Confirmed CNS activity (CNS ORR and CNS CR by BICR) may be beneficial in delaying need for brain radiation CNS ORR CNS CR Baseline MRI Week 12 MRI Non-Target CNS Lesion CNS lesion not detected 47% (8/17) 41% (7/17) In CNS evaluabl
Slide 15: FURTHER: Firmonertinib Shows a Manageable Safety Profile in NSCLC EGFR PACC
FURTHER: Firmonertinib Shows a Manageable Safety Profile in NSCLC EGFR PACC All PACC Patients All Patients in FURTHER TRAE of Clinical Interest1 for 1L PACC Patients Treatment-related adverse 160 mg 240 mg 160 mg 240 mg PACC Cohort - 160 PACC Cohort - 240 events (TRAEs), n (%) (N=31) (N=29) (N=42) (
Slide 16: ALPACCA (FURMO-006): First Randomized Global Phase 3 Study in 1L NSCLC EGFR PACC Mutations
ALPACCA (FURMO-006): First Randomized Global Phase 3 Study in 1L NSCLC EGFR PACC Mutations (NCT07185997) Key Eligibility Criteria: Endpoints: • PACC mutation* • No prior therapy for metastatic Firmonertinib disease and no prior EGFR-TKI 240 mg QD Primary endpoints: • Allows untreated brain metastase
Slide 17: Our Next-Generation ADC Pipeline Advancing In Clinical Development
Our Next-Generation ADC Pipeline Advancing In Clinical Development ARR-217 (MRG007) Improved linker-drug and conjugation technology • ARR-217 targets CDH17 which is broadly over- expressed in GI malignancies (i.e., colorectal, gastric, pancreatic) • Superior preclinical activity over conventional CD
Slide 18: Our Second ADC Pipeline Program Also Advancing In Clinical Development
Our Second ADC Pipeline Program Also Advancing In Clinical Development ARR-002 Novel Tetravalent, Dual-Targeting Antibody Drug Conjugates NaPi2b NaPi2b • ARR-002 targets NaPi2b and MUC16, which are highly expressed in ovarian and endometrial cancers, among other solid tumors including lung • First i
Slide 19: Our Additional Dual-Targeting ADCs are Advancing Toward the Clinic
Our Additional Dual-Targeting ADCs are Advancing Toward the Clinic Novel Tetravalent, Dual-Targeting Antibody Drug Conjugates • Creating a pipeline of first-in-class • ARR-421 & ARR-173 – Additional tetravalent, dual-targeting ADCs tetravalent ADC programs advancing through research partnership1 to
Slide 20: Near-Term Key Inflection Points Validate Approach & Drive Value Creation
Near-Term Key Inflection Points Validate Approach & Drive Value Creation Cash and Cash Equivalents as of June 30, 2026 of $373.1 million Firmonertinib Oral, highly CNS-penetrant TKI with Topline Pivotal Global Phase 3 Data 2H 2026 broad activity and selectivity across In 1L NSCLC EGFR exon 20 EGFR m
Slide 21: ArriVent: A Late-Stage Company With Multiple Clinical Assets in Development
ArriVent: A Late-Stage Company With Multiple Clinical Assets in Development Completed Initiated a global ARR-217, a CDH-17 ARR-002, a enrollment for Phase 3 pivotal study targeted ADC, tetravalent NaPi2b pivotal study of of firmonertinib in currently in Phase 1, and MUC16 targeting firmonertinib in
ArriVent BioPharma — Investor Presentation (August 2026) on 6ix